News & Updates
Filter by Specialty:
Higher plasma omega-3 PUFA levels tied to better large arterial elasticity
Increased plasma levels of total and individual omega-3 (n-3) polyunsaturated fatty acids (PUFAs) appear to be associated with higher large artery elasticity (LAE) among persons free of baseline cardiovascular disease (CVD), results of a multi-ethnic study have shown.
Higher plasma omega-3 PUFA levels tied to better large arterial elasticity
08 Jan 2023
Cardiovascular, mortality outcomes in hypertension similar between two thiazide diuretics
The use of chlorthalidone in the treatment of patients with hypertension does not appear to provide better protection against major cardiovascular outcome events or noncancer-related deaths when compared with hydrochlorothiazide, according to a study.
Cardiovascular, mortality outcomes in hypertension similar between two thiazide diuretics
06 Jan 2023
Edoxaban prevents thromboembolism in children with cardiac disease
Edoxaban may be used as an alternative treatment for thromboembolism (TE) prevention in children with cardiac disease showing low rates of clinically relevant bleeding and TE, suggests a study. Some of its advantages include once-daily dosing and infrequent monitoring requirement.
Edoxaban prevents thromboembolism in children with cardiac disease
04 Jan 2023
Parkinson’s, T2D drug affords cardioprotection in youth with T1D
Bromocriptine quick release, a medication used for Parkinson’s disease and type 2 diabetes (T2D), appears to confer cardiovascular benefits such as lower blood pressure (BP) and reduced aortic stiffness in teenagers with type 1 diabetes (T1D), according to data from the BCQR-T1D study.
Parkinson’s, T2D drug affords cardioprotection in youth with T1D
31 Dec 2022
Prasugrel tops ticagrelor for reducing risk of ischaemic events in ACS patients with prior MI
Prasugrel appears to better protect against the risk of ischaemic events in patients with acute coronary syndrome (ACS) and prior myocardial infarction (MI) as compared with ticagrelor, without a trade-off in bleeding, a study has found.
Prasugrel tops ticagrelor for reducing risk of ischaemic events in ACS patients with prior MI
24 Dec 2022
Pemafibrate reduces triglycerides, but not CV events, in patients with T2D, hypertriglyceridemia
Despite reducing triglyceride levels, pemafibrate does not reduce the risk of cardiovascular (CV) events among patients with type 2 diabetes (T2D) and hypertriglyceridemia, according to results of the PROMINENT trial presented at AHA 2022.